Scientists in Syria studied a type of bacteria called Parabacteroides distasonis that lives in our stomachs. They found this bacteria in some people’s stool samples and tested how well antibiotics work against it. The bacteria they found were resistant to many common antibiotics, meaning these medicines might not work well against it. However, this same bacteria might also have health benefits and could potentially be used as a probiotic in the future. This is the first study of this bacteria in Syria, and it shows we need to keep watching how this bacteria behaves to understand if it’s more helpful or harmful.
The Quick Take
- What they studied: How common is a specific gut bacteria called Parabacteroides distasonis in people living in Aleppo, Syria, and how well do antibiotics work against it?
- Who participated: 100 people from Aleppo provided stool samples. Some were healthy, and some had type 2 diabetes. The researchers used two different methods to find and study the bacteria.
- Key finding: Only 2 bacteria samples were successfully grown from 50 culture tests, but the bacteria they found were resistant to many common antibiotics. Interestingly, bacteria with a specific gene (rfbA) responded better to certain antibiotics than bacteria without this gene.
- What it means for you: This bacteria lives naturally in your gut, but the strains found in this study were tough to kill with standard antibiotics. While this bacteria might have future health benefits, we need more research to understand if it’s safe to use as a treatment. If you have an infection with this bacteria, your doctor may need to use different antibiotics than usual.
The Research Details
Researchers collected stool samples from 100 people in Aleppo Governorate. They used two different approaches to study the bacteria: 50 samples were grown in laboratory cultures to isolate the bacteria, while the other 50 samples were tested directly using a molecular technique called PCR (a method that finds bacteria DNA without growing it). The 50 samples tested by PCR came from 25 healthy people and 25 people with type 2 diabetes. Once they found the bacteria, they tested it against various antibiotics to see which ones could kill it or stop its growth.
The researchers measured something called MIC (minimum inhibitory concentration), which is basically the smallest amount of antibiotic needed to stop the bacteria from growing. Higher MIC values mean the bacteria is more resistant to that antibiotic. They also looked for specific genes in the bacteria that might affect how antibiotics work against it.
This research approach is important because it combines two different detection methods. The culture method is traditional and reliable but can miss bacteria that are hard to grow in the lab. The PCR method is more sensitive and can find bacteria even if they’re difficult to culture. By using both methods, the researchers got a more complete picture. Understanding antibiotic resistance is critical because it helps doctors know which treatments will actually work and helps public health officials track dangerous bacteria patterns.
This study has some important limitations to consider: it’s a small, regional study from one area in Syria, so the results may not apply to other parts of the world. The culture method only found 2 bacteria samples, which is a very small number to draw strong conclusions from. The study is descriptive rather than experimental, meaning it shows what’s happening but doesn’t prove cause-and-effect relationships. However, it does provide the first data on this bacteria in Syria and uses appropriate scientific methods for initial surveillance.
What the Results Show
Out of 100 stool samples, the researchers successfully isolated only 2 samples of Parabacteroides distasonis through traditional culture methods. This low recovery rate suggests the bacteria is either not very common in this population or is difficult to grow in laboratory conditions. Both isolates showed resistance to multiple antibiotics, including ampicillin, amoxicillin-clavulanate, clindamycin, metronidazole, and several cephalosporin antibiotics. This means these common medications would likely not work well against these bacteria strains.
One important discovery was that the bacteria carrying the rfbA gene showed better response to certain antibiotics (cephalosporins and cefoperazone/sulbactam) compared to bacteria without this gene. This suggests that specific genetic markers might predict how well antibiotics will work. The PCR testing of the other 50 samples (which doesn’t require growing the bacteria) confirmed the presence of this bacteria in both healthy individuals and people with diabetes, though the exact prevalence wasn’t clearly reported.
The study found that Parabacteroides distasonis was present in samples from both healthy people and those with type 2 diabetes, suggesting this bacteria naturally lives in different people’s guts regardless of health status. The presence of multidrug resistance (resistance to many different antibiotics) in the isolates is concerning because it limits treatment options if this bacteria causes infection. The identification of the rfbA gene as a potential predictor of antibiotic response opens possibilities for future genetic testing to determine which antibiotics might work best.
This is described as the first regional data on this bacteria in Syria, so direct comparisons to previous Syrian studies aren’t possible. However, Parabacteroides distasonis is known globally as a common gut bacteria with increasing research interest. Previous international studies have suggested this bacteria might have probiotic potential (health benefits), but this Syrian study shows that at least some strains carry antibiotic resistance genes. This adds to growing global concerns about antibiotic resistance in gut bacteria.
The study has several important limitations: only 2 bacteria isolates were successfully cultured, which is too small a number to make strong generalizations. The sample size of 100 people is modest and comes from only one region (Aleppo), so results may not represent all of Syria or other countries. The study doesn’t explain why the culture method was so unsuccessful—this could mean the bacteria is rare, hard to grow, or the methods need improvement. The researchers didn’t fully report how common the bacteria was in the PCR-tested samples. Additionally, antibiotic resistance can change over time and in different environments, so these findings are specific to this time and place.
The Bottom Line
Based on this research, there are no direct recommendations for the general public at this time. The findings are preliminary and regional. If you have a bacterial infection, continue following your doctor’s prescribed antibiotic treatment. If you’re considering probiotic supplements containing this bacteria, wait for more research—while it shows promise, we don’t yet know if it’s safe or effective as a treatment. Healthcare providers in Syria and similar regions should be aware that this bacteria may show resistance to common antibiotics.
Healthcare providers and public health officials in Syria and the Middle East should pay attention to these findings for surveillance purposes. Researchers studying gut bacteria and probiotics should note this data. People with type 2 diabetes might be interested since the study included diabetic participants, though no specific differences were found. People considering probiotic treatments should be cautious until more safety data is available. General public should understand this is early research and not a reason for concern about their current health.
This is surveillance research, not a treatment study, so there’s no timeline for personal health benefits. If this bacteria were to be developed as a probiotic, it would take many years of additional research and testing before it could be used as a treatment. The antibiotic resistance findings are relevant now for healthcare providers making treatment decisions.
Want to Apply This Research?
- If you’re tracking digestive health, note any changes in symptoms (bloating, gas, bowel regularity) and correlate them with dietary changes or antibiotic use. Users could log ‘antibiotic use’ events to track how their gut responds, since antibiotics can affect beneficial bacteria populations.
- Users could track their probiotic intake and note any digestive changes, though they should avoid this specific bacteria until more research is available. Instead, focus on tracking other well-established probiotics and their effects on digestion and overall wellness.
- Long-term, users should monitor their response to prescribed antibiotics and report any unusual symptoms to their healthcare provider. If this bacteria becomes available as a probiotic in the future, users could track its effects on digestive health, energy levels, and overall wellness through the app’s symptom logging feature.
This research is preliminary and region-specific. It does not provide medical advice or treatment recommendations for individuals. If you have symptoms of bacterial infection, consult your healthcare provider for proper diagnosis and treatment. Do not self-treat with probiotics or antibiotics based on this research. This bacteria has not been approved as a probiotic treatment and should not be used without medical supervision. People with compromised immune systems, serious illnesses, or those taking immunosuppressive medications should consult their doctor before considering any probiotic use. This study was conducted in Syria and may not apply to other populations or geographic regions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.